Japanese filing for mirabegron the first worldwide
This article was originally published in Scrip
Executive Summary
Astellas has filed an approval application in Japan for its first-in-class beta3-adrenoceptor agonist mirabegron (YM178), for the treatment of overactive bladder (OAB) symptoms.